fashion -WSS

fashion

author：comprehensive 2025-09-30 16:24:30 - browse：9856

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： What we owe ALS patients — and why one company fell short

leisure time

WSS

Florida Supreme Court upholds state's abortion ban

The United States is paying nearly triple for new Covid vaccines

Insurer loopholes limit power of law against surprise medical bills

Researchers test human milk's ability to repair gut microbiome

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Lawsuit highlights wrinkle for disputes over surprise medical bills

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Moonlake's readout produced a cash windfall. Risks remain

IVG is promising — but it won’t replace IVF quite yet

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Experts study whether long Covid risk adds up with each reinfection

Drug repurposing or repositioning? The language matters

Some top drug companies are starting to take action on climate

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

focus

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Researchers test human milk's ability to repair gut microbiome

Covid silver lining: Unprecedented look at human immune system

Medicare Advantage 2025 payments will dip, Biden administration says

CRISPR base editing slashes cholesterol levels in monkeys

The Karikó problem: Lessons for funding basic research

leisure time

hotspot

hotspot

explore